-
Something wrong with this record ?
Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy
T. Robak, M. Doubek, E. Ferrant, J. Diels, L. Andersone, S. Wilbertz, NC. Healy, L. Neumayr, S. van Sanden
Language English Country England, Great Britain
Document type Journal Article, Randomized Controlled Trial, Comparative Study
- MeSH
- Adenine * analogs & derivatives therapeutic use MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell * drug therapy mortality MeSH
- Immunotherapy methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Piperidines * therapeutic use administration & dosage MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use administration & dosage MeSH
- Pyrazoles * therapeutic use administration & dosage MeSH
- Pyrimidines * therapeutic use administration & dosage MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
OBJECTIVE: To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment or chemotherapy/chemoimmunotherapy-based (CT/CIT) regimens in 1L followed by ibrutinib in the second line (1L CT/CIT-2L ibrutinib) after disease progression by emulating a randomized trial comparing both treatment sequences. METHODS: Patient-level data from the RESONATE-2 trial (NCT01722487) and real-world PHEDRA databases were analyzed. Three scenarios were considered using the following data sources: (1) RESONATE-2, (2) combined RESONATE-2/PHEDRA, (3) combined RESONATE-2/PHEDRA for 1L ibrutinib and PHEDRA for 1L CT/CIT-2L ibrutinib. Propensity score-based weights and inverse probability of censoring weighting were used to adjust for baseline (Scenarios 2 and 3) and time-dependent confounding (all scenarios), and to address potential biases. A weighted Cox proportional hazards model was used to estimate the OS hazard ratio (HR) and 95% confidence interval (CI) for 1L ibrutinib versus 1L CT/CIT-2L ibrutinib. RESULTS: Results from Scenario 1 showed a significantly lower risk of death with 1L ibrutinib compared with 1L chlorambucil followed by 2L ibrutinib (HR 0.35 [95% CI 0.20-0.62]). Results from Scenarios 2 and 3 demonstrated a reduced risk of death with 1L ibrutinib compared with 1L CT/CIT-2L ibrutinib (HR 0.35 [0.21-0.61] and 0.64 [0.39-1.04], respectively). CONCLUSION: The analyses consistently showed a reduced risk of death when ibrutinib was used as a 1L treatment in CLL compared with delaying its use until 2L after CT/CIT regimens, which suggests that initiating ibrutinib in 1L is advantageous for improving survival outcomes.
Department of Hematology Hôpital Lyon Sud Lyon France
Department of Hematology Medical University of Lodz Copernicus Memorial Hospital Lodz Poland
Internal Medicine Hematology and Oncology Department University Hospital Brno Brno Czech Republic
Janssen Cilag GmbH Neuss Germany
Janssen Pharmaceutica NV Beerse Belgium
Janssen Sciences Ireland UC Cork Ireland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019522
- 003
- CZ-PrNML
- 005
- 20241024110756.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/03007995.2024.2368175 $2 doi
- 035 __
- $a (PubMed)38885086
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Robak, Tadeusz $u Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
- 245 10
- $a Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy / $c T. Robak, M. Doubek, E. Ferrant, J. Diels, L. Andersone, S. Wilbertz, NC. Healy, L. Neumayr, S. van Sanden
- 520 9_
- $a OBJECTIVE: To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment or chemotherapy/chemoimmunotherapy-based (CT/CIT) regimens in 1L followed by ibrutinib in the second line (1L CT/CIT-2L ibrutinib) after disease progression by emulating a randomized trial comparing both treatment sequences. METHODS: Patient-level data from the RESONATE-2 trial (NCT01722487) and real-world PHEDRA databases were analyzed. Three scenarios were considered using the following data sources: (1) RESONATE-2, (2) combined RESONATE-2/PHEDRA, (3) combined RESONATE-2/PHEDRA for 1L ibrutinib and PHEDRA for 1L CT/CIT-2L ibrutinib. Propensity score-based weights and inverse probability of censoring weighting were used to adjust for baseline (Scenarios 2 and 3) and time-dependent confounding (all scenarios), and to address potential biases. A weighted Cox proportional hazards model was used to estimate the OS hazard ratio (HR) and 95% confidence interval (CI) for 1L ibrutinib versus 1L CT/CIT-2L ibrutinib. RESULTS: Results from Scenario 1 showed a significantly lower risk of death with 1L ibrutinib compared with 1L chlorambucil followed by 2L ibrutinib (HR 0.35 [95% CI 0.20-0.62]). Results from Scenarios 2 and 3 demonstrated a reduced risk of death with 1L ibrutinib compared with 1L CT/CIT-2L ibrutinib (HR 0.35 [0.21-0.61] and 0.64 [0.39-1.04], respectively). CONCLUSION: The analyses consistently showed a reduced risk of death when ibrutinib was used as a 1L treatment in CLL compared with delaying its use until 2L after CT/CIT regimens, which suggests that initiating ibrutinib in 1L is advantageous for improving survival outcomes.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a adenin $x analogy a deriváty $x terapeutické užití $7 D000225
- 650 12
- $a chronická lymfatická leukemie $x farmakoterapie $x mortalita $7 D015451
- 650 12
- $a piperidiny $x terapeutické užití $x aplikace a dávkování $7 D010880
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a pyrimidiny $x terapeutické užití $x aplikace a dávkování $7 D011743
- 650 12
- $a pyrazoly $x terapeutické užití $x aplikace a dávkování $7 D011720
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x aplikace a dávkování $7 D000971
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Doubek, Michael $u Internal Medicine - Hematology and Oncology Department, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Ferrant, Emmanuelle $u Department of Hematology, Hôpital Lyon-Sud, Lyon, France
- 700 1_
- $a Diels, Joris $u Janssen Pharmaceutica NV, Beerse, Belgium
- 700 1_
- $a Andersone, Liva $u UAB "JOHNSON & JOHNSON" filiale Latvija, Riga, Latvia
- 700 1_
- $a Wilbertz, Sabine $u Janssen-Cilag GmbH, Neuss, Germany
- 700 1_
- $a Healy, Nollaig C $u Janssen Sciences Ireland UC, Cork, Ireland
- 700 1_
- $a Neumayr, Lynne $u Pharmacyclics, an AbbVie Company, Sunnyvale, California, USA
- 700 1_
- $a van Sanden, Suzy $u Janssen Pharmaceutica NV, Beerse, Belgium
- 773 0_
- $w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 40, č. 8 (2024), s. 1369-1378
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38885086 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110750 $b ABA008
- 999 __
- $a ok $b bmc $g 2202009 $s 1231495
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 40 $c 8 $d 1369-1378 $e 20240701 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
- LZP __
- $a Pubmed-20241015
